Aurora Cannabis management commentary cites higher adjusted SG&A as driver of Q2 fiscal 2027 adjusted EBITDA decline
ACB•Aurora Cannabis said adjusted EBITDA fell to $14 million from $15.4 million, citing higher selling costs. International medical cannabis revenue rose to $61.4 million, while Canadian medical revenue fell to $21.2 million.
1. Quarterly results
Aurora Cannabis management attributed the decline in second-quarter fiscal 2027 adjusted EBITDA to higher selling costs. International medical cannabis net revenue rose to $61.4 million on stronger patient demand in Germany and Poland, while Canadian medical cannabis net revenue fell to $21.2 million as reimbursement cuts reduced revenue; medical adjusted gross margin narrowed to 62%. Net loss from continuing operations narrowed to $21.1 million from $27.2 million, and free cash outflow decreased to $17.5 million from $39.9 million.
